Evidence map›Paper›PMID 7541609›Full record

ArticleThe American journal of pathology1995

Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection.

S D Bergese, E H Huang, R P Pelletier, M B Widmer, R M Ferguson, C G Orosz

Abstract read
In one paragraph

Article in The American journal of pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Inhibition of angiogenesis by interleukin 4.The Journal of experimental medicine · 1998
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

S D BergeseDepartment of Surgery, Ohio State University College of Medicine, Columbus, OH 43210, USA.
E H Huang
R P Pelletier
M B Widmer
R M Ferguson
C G Orosz
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI WANCAI YANG · 1985 to 2026
$132.3M
LYMPHOCYTE ENDOTHELIAL INTERACTIONS IN REJECTIONR01DK034774 · NIDDK · OHIO STATE UNIVERSITY · PI OROSZ, CHARLES G · 1986 to 1993
–
ALLOGRAFT REJECTION, TOLERANCE AND VCAM-1R01HL050478 · NHLBI · OHIO STATE UNIVERSITY · PI OROSZ, CHARLES G · 1993 to 1996
–
NCI NIH HHS P30 CA1605814NHLBI NIH HHS R01-HL50478NIDDK NIH HHS R01-DK34774
6 · The paper itself

Abstract

This report provides evidence to support the hypothesis that tumor necrosis factor-alpha (TNF-alpha) and IL-4 promote the expression of new endothelial surface molecules in rejecting murine heterotopic cardiac allografts. The microvascular endothelia of these cardiac allografts all develop strong reactivity with the monoclonal antibodies (mAbs) YN1.1/74 (anti-ICAM-1), M/K-2 (anti-VCAM-1) and MECA-32 (undefined molecule) within 3 to 5 days of graft implantation. Daily treatment of the allograft recipients with pentoxifylline (PTX), soluble TNF receptor (TNFR:Fc), anti-interleukin-4 (IL-4) mAb (11B11), or soluble IL-4 receptor, each abrogate the expression of endothelial VCAM-1 and reduce the endothelial reactivity with the mAbs YN1.1/74 and MECA-32 to levels found in cardiac isografts. This is accompanied by a reduction, but not an elimination, of interstitial leukocytic infiltration. Despite this, cardiac allograft recipients treated with PTX or the mAb 11B11 rejected allografts at the same rate as untreated allograft recipients, ie, within 10 to 12 days after graft implantation. These rejected grafts contained mRNAs for TNF-alpha and IL-4, as well as for all other cytokines that have been associated with rejecting allografts. This suggests that endothelial VCAM-1 expression, which is characteristic of rejection, is not an essential element of the rejection process. Interestingly, the grafts from the PTX-treated recipients continued to display rare, isolated VCAM-1 positive cells in the interstitium, which may be dendritic cells. In general, these studies demonstrate a role for IL-4 and TNF-alpha in the alterations of vascular endothelial phenotype observed in rejecting cardiac allografts. They also demonstrate that endothelial VCAM-1 expression is not essential for the allograft rejection process, and that the role of VCAM-1 in this process may be more subtle than was initially suspected.

Indexed as

Heart TransplantationAnimalsAntibodies, MonoclonalBase SequenceCell Adhesion MoleculesDNA PrimersEndothelium, VascularFemaleGraft RejectionImmunoenzyme TechniquesInterferon-alphaInterleukin-4MiceMice, Inbred C57BLMice, Inbred DBAMolecular Sequence DataAntibodies, MonoclonalCell Adhesion MoleculesDNA PrimersInterferon-alphaInterleukin-4PentoxifyllineReceptors, Tumor Necrosis FactorRNA, MessengerVascular Cell Adhesion Molecule-1

Identifiers

PMID7541609
PMCPMC1869871
OpenAlexW326893089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.